Literature DB >> 29804157

The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia-continuous selective intracarotid nimodipine therapy in awake patients without sedation.

Andrej Paľa1, Max Schneider2, Christine Brand2, Maria Teresa Pedro2, Yigit Özpeynirci3, Bernd Schmitz3, Christian Rainer Wirtz2, Thomas Kapapa2, Ralph König2, Michael Braun3.   

Abstract

Cerebral vasospasm (CV) and delayed cerebral ischemia (DCI) are major factors that limit good outcome in patients with spontaneous subarachnoid hemorrhage (SAH). Continuous therapy with intra-arterial calcium channel blockers has been introduced as a new step in the invasive treatment cascade of CV and DCI. Sedation is routinely necessary for this procedure. We report about the feasibility to apply this therapy in awake compliant patients without intubation and sedation. Out of 67 patients with invasive endovascular treatment of cerebral vasospasm due to spontaneous SAH, 5 patients underwent continuous superselective intracarotid nimodipine therapy without intubation and sedation. Complications, neurological improvement, and outcome at discharge were summarized. Very good outcome was achieved in all 5 patients. The Barthel scale was 100 and the modified Rankin scale 0-1 in all cases at discharge. We found no severe complications and excellent neurological monitoring was possible in all cases due to patients' alert status. Symptoms of DCI resolved within 24 h in all 5 cases. We could demonstrate the feasibility and safety of selective intracarotid arterial nimodipine treatment in awake, compliant patients with spontaneous SAH and symptomatic CV and DCI. Using this method, an excellent monitoring of neurological function as well as early detection of other complications is possible. It might be an important step in the risk reduction of invasive CV therapy to improve the outcome with CV and DCI after SAH in selected patients.

Entities:  

Keywords:  Continuous intra-arterial infusion; Delayed cerebral ischemia; Nimodipine; Subarachnoid hemorrhage; Vasospasm

Mesh:

Substances:

Year:  2018        PMID: 29804157     DOI: 10.1007/s10143-018-0986-5

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  5 in total

1.  Safety and efficacy of nimodipine combined with flunarizine in patients with angioneurotic headache.

Authors:  Tao Zhang; Yao Xiao; Shengquan Li
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Intraarterial Nimodipine Versus Induced Hypertension for Delayed Cerebral Ischemia: A Modified Treatment Protocol.

Authors:  Miriam Weiss; Walid Albanna; Catharina Conzen-Dilger; Nick Kastenholz; Katharina Seyfried; Hani Ridwan; Martin Wiesmann; Michael Veldeman; Tobias Philip Schmidt; Murad Megjhani; Henna Schulze-Steinen; Hans Clusmann; Marinus Johannes Hermanus Aries; Soojin Park; Gerrit Alexander Schubert
Journal:  Stroke       Date:  2022-06-08       Impact factor: 10.170

Review 3.  Neurocritical care management of poor-grade subarachnoid hemorrhage: Unjustified nihilism to reasonable optimism.

Authors:  Fawaz Al-Mufti; Stephan A Mayer; Gurmeen Kaur; Daniel Bassily; Boyi Li; Matthew L Holstein; Jood Ani; Nicole E Matluck; Haris Kamal; Rolla Nuoman; Christian A Bowers; Faizan S Ali; Hussein Al-Shammari; Mohammad El-Ghanem; Chirag Gandhi; Krishna Amuluru
Journal:  Neuroradiol J       Date:  2021-09-03

4.  Adverse Events and Complications in Continuous Intra-arterial Nimodipine Infusion Therapy After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Thomas Kapapa; Ralph König; Benjamin Mayer; Michael Braun; Bernd Schmitz; Silwia Müller; Julia Schick; Christian Rainer Wirtz; Andrej Pala
Journal:  Front Neurol       Date:  2022-02-18       Impact factor: 4.003

5.  The Local Intraarterial Administration of Nimodipine Might Positively Affect Clinical Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia.

Authors:  Johannes Walter; Martin Grutza; Markus Möhlenbruch; Dominik Vollherbst; Lidia Vogt; Andreas Unterberg; Klaus Zweckberger
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.